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The destruction of pluripotent stem cell-derived grafts by the host immune system presents a significant
barrier to clinical translation of cell therapies. Pearl et al. (2011) report in this issue ofCell StemCell that a brief,
nontoxic immunosuppressive regimen, achieved by blockade of leucocyte costimulatory pathways, may
overcome this problem.The issue of the immunogenicity of grafts
derived from human embryonic stem cells
(ESCs) has been a challenge to the field of
regenerative medicine from the begin-
ning. The very low levels of expression
of HLA Class I and the absence of HLA
Class II molecules on the surface of undif-
ferentiated ESCs gave rise to early opti-
mism that ESC-derived grafts might
evade immune surveillance. This opti-
mism was tempered, however, by the
finding that, unsurprisingly, expression of
HLA Class I molecules rises following
differentiation of ESCs into somatic line-
ages and by subsequent reports that
showed mouse and human ESCs them-
selves were visible to the immune system
in vitro and subject to rejection in vivo (re-
viewed in Chidgey and Boyd, 2008).
Many potential solutions to this
problem have been proposed (Chidgey
et al., 2008). Some involve tailoring the
graft to fit the host. Somatic cell nuclear
transfer, the first strategy put forward to
provide patient-specific stem cell lines,
foundered on the inefficiency of reprog-
ramming by nuclear transfer and inherent
difficulties in obtaining sufficient numbers
of human oocytes to carry out the proce-
dure. The discovery of induced pluripo-
tent stem cells (iPSCs) would appear to
provide a genuinely viable approach to
the generation of patient-specific stem
cell lines. However, many questions
remain over the genetic stability of iPSCs,
their safety, and their bioequivalence
to ESCs. Though these problems will
probably be overcome in due course,
the logistical challenges of producing
patient-specific iPSC lines with the
required differentiation capability and
safety profile will probably mean that the246 Cell Stem Cell 8, March 4, 2011 ª2011 Eultimate use of the technology will be
through the development of large banks
of cell lines to provide approximate tissue
matching for patients. If this turns out to
be the case, the problem of tissue rejec-
tion because of residual mismatches will
still need to be addressed.
Thus, ongoing research continues to
seek means to modulate the host immune
system to provide for lasting engraftment
during stem cell-based therapies.
Conventional immunosuppression with
drugs targeting the calcineurin or mTOR
pathways provides one answer. This
approach is being used by Geron in the
first phase 1 trial of an ESC therapeutic
even though the oligodendrocyte
precursor cells used in this trial were
previously shown to evade immune attack
in assays in vitro (Okamura et al., 2007).
However, these compounds are toxic
after long-term administration. Alterna-
tively, central or thymic tolerance might
be achieved by transplantation of ESC-
or iPS-derived hematopoietic stem cells
to achieve partial chimerism prior to
engraftment of other tissues generated
from the same stem cell line. Hematopoi-
etic stem cells or their progeny can enter
the thymus and give rise to antigen-
presenting cells that will delete donor
reactive T cells, resulting in subsequent
tolerance of stem cell grafts derived
from the same source. A similar result
might be obtained by administering
antigen-presenting cells, for example,
dendritic cells of donor (stem cell line)
origin. Difficulties with these strat-
egies include our current inability to
achieve long-term engraftment with
ESC-derived hematopoietic progenitors
and the fact that the thymus, critical tolsevier Inc.establishment of central tolerance, atro-
phies with age.
Wu and colleagues describe their
approach in this issue of Cell Stem Cell
(Pearl et al., 2011), which involved
suppression of T cell costimulatory path-
ways. Previous work by this group had
shown that ESC graft rejection was largely
T cell-mediated (Swijnenburg et al., 2008).
A T cell response involves two steps: liga-
tion of a foreign antigen to the T cell
receptor and activation of the T cell by
the interaction of costimulatory mole-
cules. Pearl et al. (2011) blocked the
costimulatory pathway by the use of
monoclonal antibodies that inhibit two
key receptor-ligand pairs: the tumor
necrosis factor superfamily receptor
member CD40 and its ligand, involved in
many aspects of T cell activation, and
the integrin LFA-1 and ICAM1, critical for
intimate interactions between T cells and
antigen presenting cells. These agents
were combined with activation of an
inhibitor of costimulation, CTLA4. The
study examined mouse ESCs, which
allowed for comparison of graft survival
in syngeneic and allogeneic settings,
alongside human ESC- and iPSC-derived
xenografts in mice (Pearl et al., 2011). By
marking the cells with firefly luciferase,
the group could monitor graft progression
in vivo using bioluminescence. A brief
treatment with the combination of
reagents listed above enabled long-term
engraftment of human and mouse ESCs
and iPSCs and differentiated cells derived
from them. Importantly, this immunosup-
pressive regimen did not inhibit the ability
of the host to respond to other foreign
antigens. A previous study had also
shown that blockade of costimulatory
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Previewspathways enhanced human ESC engraft-
ment (into the testis of immunocompetent
mice [Grinnemo et al., 2008]). These
authors postulated that the tolerance
involved T regulatory (Treg)cells; how-
ever, Pearl et al. (2011) found that Treg
activity probably did not account for
immunosuppressive effects in their
model.
These results provide promising proof
of concept for the use of costimulatory
blockade and short-term immunosup-
pression to enable engraftment in ESC
or iPSC therapies. However, extensive
preclinical and clinical experience with
costimulatory blockade has shown that
promising results in mouse models are
not always borne out in studies in
nonhuman primates or in human trials
(Ford and Larsen, 2009). Three host
factors can limit the efficacy and duration
of costimulatory blockade regimens (Ford
and Larsen, 2009). The first is the level ofT cell precursors present before therapy,
since high levels can bypass the need
for strong costimulation. The second
factor is the presence of memory T cells
with cross reactivity to graft antigens
and which do not require strong stimula-
tion for activation, again obviating the
need for costimulation. Finally, interferon
can influence both costimulation and graft
survival with potentially opposing effects
on outcomes. These considerations
notwithstanding, costimulatory blockade
is constantly undergoing refinement and
improved reagents are becoming avail-
able. The studies of Pearl et al. (2011)
provide a firm foundation for future trans-
lational studies of less toxic immunosup-
pressive regimens in stem cell therapies.REFERENCES
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Recently in Nature, Davidson and coworkers (Diep et al., 2011) identified nephron progenitors/stem cells
located at the point of fusion with the pronephric tubules in adult zebrafish. Clumps of progenitors give
rise to functional nephrons after serial transplantation, demonstrating the ability of tissue stem cells to regen-
erate damaged kidney structures.The adult mammalian kidney is developed
through reciprocal inductive interactions
between the metanephric mesenchyme
(MM) and adjacent ureteric bud (UB)
(Dressler, 2006). The UB will outgrow to
form the collecting ducts, and the MM
cells will give rise to nephrons (Figure 1),
the functional units of the kidney. The prin-
cipal function of the nephrons is to keep
blood clean and chemically balanced.
The nephron comprises a blood filter,
called the glomerulus, and a renal tubule,
which measures useful chemicals and
releases them back to the blood for body
use. The development and function of the
kidney are evolutionarily conserved fromhuman to fish and even to fly (Figure 1;
Weavers et al., 2009; Wingert and David-
son, 2008). Loss of nephron function
underliesmost kidneydiseases.Mammals
can only partly repair their damaged neph-
rons and are unable to generate newones.
In contrast, throughout their lifespan, fish
are able to add new nephrons and regen-
erate nephrons de novo after injury. The
question of what cell population(s) may
be responsible for this enhanced degree
of adult organ regeneration and repair
was addressed recently by Davidson and
colleagues (Diep et al., 2011).
To identify the source of nephron
regeneration in adult zebrafish, Davidsonand colleagues performed a series of
transplantation experiments (Diep et al.,
2011). The recipient fish were first immu-
nocompromised by radiation to prevent
graft rejection and then injected with
gentamicin (an established nephrotoxin)
to induce nephron damage. Unpurified
whole-kidney marrow cells (WKM) that
express fluorescent reporters in the distal
nephron (approximately 5 3 105 cells)
were prepared from donors and injected
into the head region of the kidney of recip-
ient fish. The authors demonstrated that
the donor cells were fully capable of gen-
erating donor-derived nephrons in 100%
of the recipients. The donor-derivedll 8, March 4, 2011 ª2011 Elsevier Inc. 247
